ArticleDermatology practical & conceptual2026
Diagnostic Yield of Abdominal Wall Fat Pad Biopsy for Systemic Amyloidosis in a Low-Prevalence Referral Cohort.
Article in Dermatology practical & conceptual, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionSystemic amyloidosis is a rare disorder characterized by extracellular amyloid deposition in tissues, leading to variable organ dysfunction. Abdominal wall fat pad biopsy is widely used as a minimally invasive diagnostic approach, yet its sensitivity varies according to population and technique.
objectivesTo assess the diagnostic yield and adequacy of abdominal wall fat pad biopsy for systemic amyloidosis in a low-prevalence referral cohort.
methodsA retrospective study was conducted at a tertiary university hospital including all consecutive abdominal wall fat pad biopsies performed between January 2021 and June 2025. Clinical data, histopathological findings, and biopsy techniques were reviewed. Adequacy was defined by the presence of well-preserved subcutaneous fat with vascular and stromal structures. Congo red-positive deposits showing apple-green birefringence confirmed amyloidosis.
resultsA total of 106 biopsies from 103 patients (mean age 71.1 ± 12.2 years; 56.3% male) were analyzed. Clinical indications included MGUS (65.0%), multiple myeloma (27.2%), and suspected infiltrative cardiomyopathy or nephrotic proteinuria (8%). Overall, 7/106 biopsies (6.6%) were positive for amyloid. Sensitivity among patients with known systemic amyloidosis was 66.6% (6/9), and specificity was 100%. Only two of 94 patients (2.1%) without prior diagnosis were newly identified. Three punch biopsies (2.8%) were inadequate due to insufficient fat.
conclusionsAbdominal wall fat pad biopsy is safe and minimally invasive but demonstrates limited diagnostic yield in unselected low-risk populations. It should not be used as a screening tool in patients with monoclonal gammopathies without organ involvement. Adequate tissue sampling and careful patient selection are essential to optimize diagnostic performance.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.